- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01852942
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
This study was designed to test the hypothesis that treatment of HIV infected subjects with losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will:
- reverse existing lymphoid tissue fibrosis,
- restore lymphoid tissue architecture,
- increase the number and improve the function of peripheral and lymphatic CD4 T cells,
- decrease levels of systemic immune activation (IA),
- decrease size of the HIV reservoir, and
- be safe and well tolerated.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a randomized, double-blind, placebo-controlled trial of 50 HIV-1 infected individuals on stable ART randomized in a 1:1 ratio to losartan (50 mg orally daily titrated to 100 mg daily) vs placebo for 30 months. We plan to enroll a total of 63 HIV infected subjects to ensure that 50 complete the protocol. All HIV infected subjects will undergo biopsies of inguinal lymph node (LN) and gut associated lymphatic tissue (GALT) for primary endpoint analysis at baseline, 12 and 30 months after study enrollment. Blood will be collected at least quarterly throughout the study and an intensive blood pharmacokinetic (PK) study will be conducted at month 1. All HIV infected subjects will be vaccinated with the quadrivalent human papillomavirus (HPV) vaccine at months 23, 25 and 29.5 to measure immune function. 5 HIV uninfected control subjects will also be enrolled.
The primary endpoint is to determine the impact of losartan on lymphoid tissue fibrosis in HIV infected, ART treated adults. This will be determined by measuring the amount of collagen deposition in lymphoid tissues and the integrity of the FRCn using immunohistochemistry (IHC) and quantitative image analysis (QIA).
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota, Division of Infectious Diseases
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
HIV infected participants:
Inclusion Criteria:
Participants must meet all of the following inclusion criteria to participate in this study:
HIV-1 infected.
-≥ 18 years of age.
Baseline peripheral CD4+ T cell count 200-600 cells/mm3 for at least two measures over the 6 months prior to study enrollment.
-≥ 12 months of stable ART, defined as use of a given drug regimen without disruption lasting ≥ 1 week in the period leading up to study enrollment.
- HIV viral load (VL) < 50 copies/mL for at least two consecutive measures over the 6 months prior to study enrollment.
- No contraindication to proposed study procedures.
- Women of child-bearing potential must be willing to use a form of effective contraception for the duration of the study. Effective contraception includes hormonal injection, implant or oral medication, IUD, diaphragm, or cervical cap with spermicide. Condoms cannot be used as the sole form of contraception.
Exclusion Criteria: Participants meeting any of the following exclusion criteria at baseline will be excluded from study participation:
- Use of any immunomodulator within the 12 months prior to study enrollment. An immunomodulator for the purposes of this study is defined as a drug known to either diminish or augment a patient's immune system. Examples of these include, but are not limited to, systemic corticosteroids (use of topical steroids will be permitted), TNF-inhibitors, rituximab, cyclophosphamide, abatacept,cyclosporine, azathioprine, 6-mercaptopurine, methotrexate, sulfasalazine, cyclosporine, tacrolimus,sirolimus, and intravenous immune globulin.
- Current use of an ARB or ACEi.
- Current use of rifaximin, fluconazole or lithium given potential for drug interactions with losartan.
- Prior reaction or intolerance to an ARB or ACEi.
- Prior diagnosis of a chronic inflammatory disease with serologic or clinical evidence as diagnosed by a primary care physician or specialist. Examples of these include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome, mixed connective tissue disease, psoriasis, polymyositis, dermatomyositis, vasculitis, sarcoidosis, Wegener's granulomatosis, giant cell arteritis, polyarteritis nodosa, gastrointestinal pemphigoid, eosinophilic colitis, Crohn's disease, ulcerative colitis, autoimmune hepatitis, and hepatitis C.
- Prior diagnosis of a connective tissue disease with genetic, serologic or clinical evidence as diagnosed by a primary care physician or specialist (Marfan's syndrome, Ehlers-Danlos syndrome).
- Baseline blood pressure < 110/70.
- Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 within 4 weeks of study initiation or history of advanced renal disease.
- AST and/or ALT > 3 times the upper limit of normal within 4 weeks of study enrollment.
- Potassium > 5.0 within 4 weeks of study enrollment.
- Pregnancy.
- In women of childbearing age, unwillingness to use birth control for the duration of the study.
- Breast feeding.
- Prior vaccination with an HPV vaccine, including Cervarix (GlaxoSmithKline) or Gardasil (Merck).
- History of hypersensitivity or severe allergic reactions to yeast.
HIV-uninfected:
Inclusion Criteria
Participants must meet all of the following inclusion criteria to participate in this study:
HIV uninfected.
-≥ 18 years of age.
- No contraindication to proposed study procedures.
Exclusion Criteria: Participants meeting any of the following exclusion criteria at baseline will be excluded from study participation:
- Use of any immunomodulator within the 12 months prior to study enrollment (as defined above).
- Current use of an ARB or ACEi.
- Prior diagnosis of a chronic inflammatory disease with serologic or clinical evidence (as defined above).
- Prior diagnosis of a connective tissue disease with genetic, serologic or clinical evidence as diagnosed by a primary care physician or specialist (Marfan's syndrome, Ehlers-Danlos syndrome).
- Pregnancy.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador de Placebo: Pílula de açúcar
|
one tablet by mouth daily
|
Experimental: Losartana
|
Participants will start with 50 mg of losartan by mouth daily.
The dose will be increased to 100 mg by mouth daily after 14 days.
The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Collagen Deposition in LT
Prazo: 30 months
|
The Impact of Losartan Treatment on Lymphoid Tissue (LT) Fibrosis will be determined by measuring the amount of collagen deposition in LT using immunohistochemistry (IHC) and quantitative image analysis (QIA).
LT will be obtained at baseline, month 12 and month 30.
|
30 months
|
Integrity of the Fibroblastic Reticular Cell Network (FRCn)
Prazo: 30 months
|
The Impact of Losartan Treatment on Lymphoid Tissue (LT) Fibrosis will be determined by measuring the Integrity of the fibroblastic reticular cell network (FRCn) using immunohistochemistry (IHC) and quantitative image analysis (QIA).
LT will be obtained at baseline, month 12 and month 30.
|
30 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Frequency of CD4+ T Cells
Prazo: 30 months
|
Impact of losartan on immune reconstitution and function will be determined by frequency of CD4+ T cells in LT using IHC.
|
30 months
|
Frequency TUNEL+CD3+CD8+ T Cells
Prazo: 30 months
|
Impact of losartan on immune reconstitution and function will be determined by frequency of TUNEL+CD3+CD8+ T cells in LT using IHC.
|
30 months
|
Frequency of Cells Expressing TGF-beta and Lymphotoxin-beta
Prazo: 30 months
|
Impact of losartan on immune reconstitution and function will be determined by frequency of cells expressing TGF-beta and lymphotoxin-beta in LT using IHC.
|
30 months
|
Serum Concentration of IL-7
Prazo: 30 months
|
Impact of losartan on immune reconstitution and function will be determine by serum concentrations of IL-7 measured with ELISA.
|
30 months
|
Serum Concentration of TGF-beta
Prazo: 30 months
|
Impact of losartan on immune reconstitution and function will be determine by serum concentrations of TGF-beta measured with ELISA.
|
30 months
|
Immune Response to HPV Vaccination
Prazo: 30 months
|
Impact of losartan on immune reconstitution and function will be determine by measuring the immune response to HPV vaccination using flow cytometry to identify cells stimulated by specific HPV peptides.
|
30 months
|
Frequency of Activated T-cell Populations - Immunofluorescent Staining
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the frequency of activated T-cell populations (specifically CD3+CD4+CD38+, CD3+,CD8+CD38+,CD4+Ki67+ and CD8+Ki67+ T cells) in LT using immunofluorescence staining
|
30 months
|
Percent of Activated T Cells in PBMCs - Flow Cytometry
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated T cells in peripheral blood mononuclear cells (PBMCs) using flow cytometry.
|
30 months
|
Percent of Activated Macrophages in PBMCs - Flow Cytometry
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated macrophages in peripheral blood mononuclear cells (PBMCs) using flow cytometry.
|
30 months
|
Percent of Activated Dendritic Cells in PBMCs - Flow Cytometry
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated dendritic cells in peripheral blood mononuclear cells (PBMCs) using flow cytometry.
|
30 months
|
Percent of Activated T Cells in LT - Flow Cytometry
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated T cells in lymphoid tissues (LT) using flow cytometry.
|
30 months
|
Percent of Activated Macrophages in LT - Flow Cytometry
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated macrophages in lymphoid tissues (LT) using flow cytometry.
|
30 months
|
Percent of Activated Dendritic Cells in LT - Flow Cytometry
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated dendritic cells in lymphoid tissues (LT) using flow cytometry.
|
30 months
|
Intracellular Concentration of IL-17 in PBMCs
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-17 in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of IFNg in PBMCs
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IFNg in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-2 in PBMCs
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-2 in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of TNF in PBMCs
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine TNF in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-10 in PBMCs
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-10 in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of GM-CSF in PBMCs
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine GM-CSF in PBMCs using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-17 in LT
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-17 in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of IFNg in LT
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IFNg in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-2 in LT
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-2 in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of TNF in LT
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine TNF in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of IL-10 in LT
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-10 in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Intracellular Concentration of GM-CSF in LT
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine GM-CSF in lymphoid tissue (LT) using cytokine staining.
|
30 months
|
Plasma Concentration of LPS
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of LPS by ELISA.
|
30 months
|
Plasma Concentration of sCD14
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of sCD14 by limulus assay.
|
30 months
|
Plasma Concentration of I-FABP
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of I-FABP using ELISA.
|
30 months
|
Plasma Concentration of IL-1b
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of IL-1b using ELISA.
|
30 months
|
Plasma Concentration of IL-1RA
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of IL-1RA using ELISA.
|
30 months
|
Plasma Concentration of IL-6
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of IL-6 using ELISA.
|
30 months
|
Plasma Concentration of TNF
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of TNF using ELISA.
|
30 months
|
Plasma Concentration of Amyloid A
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of amyloid A using ELISA.
|
30 months
|
Plasma Concentration of CRP
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of CRP using ELISA.
|
30 months
|
Plasma Concentration of D-dimer
Prazo: 30 months
|
The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of D-dimer using ELISA.
|
30 months
|
Frequency of HIV RNA+ and DNA+ Cells in LN - Radiolabeled ISH
Prazo: 30 months
|
The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in LN using radiolabeled in situ hybridization (ISH).
|
30 months
|
Frequency of HIV RNA+ and DNA+ Cells in LN - RNAscopeTM in Situ Technology
Prazo: 30 months
|
The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in LN using RNAscopeTM in situ technology.
|
30 months
|
Frequency of HIV RNA+ and DNA+ Cells in GALT - Radiolabeled in Situ Hybridization (ISH)
Prazo: 30 months
|
The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in GALT radiolabeled in situ hybridization (ISH).
|
30 months
|
Frequency of HIV RNA+ and DNA+ Cells in GALT - RNAscopeTM in Situ Technology
Prazo: 30 months
|
The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in GALT using RNAscopeTM in situ technology.
|
30 months
|
Concentration of Losartan and Antiretrovirals (ARVs)
Prazo: 30 months
|
Potential Drug-drug Interactions Between Losartan and Antiretrovirals (ARVs) will be assessed by measuring levels of ARVs and losartan in plasma and peripheral blood mononuclear cells (PBMCs).
|
30 months
|
Intracellular Concentration of Losartan and Antiretrovirals (ARVs)
Prazo: 30 months
|
Potential Drug-drug Interactions Between Losartan and Antiretrovirals (ARVs) will be assessed by measuring intracellular concentration of losartan and ARVs in lympoidtissue.
|
30 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Frequency of Dendritic Cell and CD4 T Cell Interactions With the FRCn
Prazo: 30 months
|
As an exploratory endpoint, we will determine the impact of losartan on frequency of dendritic cell and CD4 T cell interactions with the FRCn.
This will be determined using two-photon microscopy in sections on LN obtained from study subjects.
Given that this is an exploratory endpoint, these assays will be performed in a subset of subjects (5 losartan treated, 2 placebo treated and 5 HIV uninfected controls).
|
30 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Timothy Schacker, M.D., University of Minnesota
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Processos Patológicos
- Infecções por vírus de RNA
- Doenças Virais
- Infecções transmitidas pelo sangue
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Síndromes de Deficiência Imunológica
- Doenças do sistema imunológico
- Atributos da doença
- Doenças de Vírus Lento
- Fibrose
- Infecções por HIV
- Infecções
- Doenças Transmissíveis
- Síndrome da Imunodeficiência Adquirida
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Antiarrítmicos
- Anti-hipertensivos
- Bloqueadores dos receptores tipo 1 da angiotensina II
- Antagonistas dos Receptores da Angiotensina
- Losartana
Outros números de identificação do estudo
- 1111M06585
- 13-3613 (Outro identificador: Hennepin County Medical Center)
- U01AI105872 (Concessão/Contrato do NIH dos EUA)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Infecções por HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecrutamentoHIV | Teste de HIV | Ligação do HIV ao Cuidado | Tratamento de HIVEstados Unidos
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement e outros colaboradoresDesconhecidoHIV | Crianças não infectadas pelo HIV | Crianças expostas ao HIVCamarões
-
University of MinnesotaRetiradoInfecções por HIV | HIV/AIDS | HIV | AUXILIA | Aids/problema de HIV | AIDS e InfecçõesEstados Unidos
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationConcluídoTeste de HIV do parceiro | Aconselhamento de casal HIV | Comunicação de casal | Incidência de HIVCamarões, República Dominicana, Geórgia, Índia
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... e outros colaboradoresRecrutamentoHIV | Teste de HIV | Vinculação ao cuidadoÁfrica do Sul
-
CDC FoundationGilead SciencesDesconhecidoProfilaxia pré-exposição ao HIV | Quimioprofilaxia HIVEstados Unidos
-
Erasmus Medical CenterAinda não está recrutandoInfecções por HIV | HIV | Infecção por HIV-1 | Infecção HIV IHolanda
-
Helios SaludViiV HealthcareDesconhecidoHIV | Infecção por HIV-1Argentina
-
National Taiwan UniversityRecrutamento
-
University of Maryland, BaltimoreRetiradoHIV | Transplante de rim | Reservatório de HIV | CCR5Estados Unidos
Ensaios clínicos em Losartan
-
wanglinConcluídoNefropatia Membranosa IdiopáticaChina
-
Merck Sharp & Dohme LLCConcluído
-
University of CambridgeBritish Heart FoundationDesconhecidoHipertensão essencial | Hipertensão Resistente à Terapia ConvencionalReino Unido
-
Mostafa Hassanein, MscConcluídoLesão Esportiva | Lesão Muscular | PRP | Losartana
-
The University of The West IndiesCaribbean College of Family PhysiciansRetiradoHipertensão | Diabetes MellitusJamaica
-
SanofiConcluídoHipertensãoEstados Unidos, Canadá, Brasil, Polônia, Federação Russa, Alemanha, Itália, Holanda, Portugal, Espanha, Peru, Malásia, Cingapura, Taiwan, México, Argentina, Republica da Coréia, Chile, Hong Kong, África do Sul, Grécia
-
Yokohama City University Medical CenterConcluído
-
EMSSuspenso
-
GlaxoSmithKlineConcluído
-
Hanmi Pharmaceutical Company LimitedConcluído